Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by co-targeting MEK and IGF-1R/PI3K

BRAF is an attractive target for melanoma drug development. However, resistance to BRAF inhibitors is a significant clinical challenge. We describe a model of resistance to BRAF inhibitors developed by chronic treatment of BRAF(V600E) melanoma cells with the BRAF inhibitor SB-590885; these cells are...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Villanueva, Jessie, Vultur, Adina, Lee, John T., Somasundaram, Rajasekharan, Fukunaga-Kalabis, Mizuho, Cipolla, Angela K., Wubbenhorst, Bradley, Xu, Xiaowei, Gimotty, Phyllis A., Kee, Damien, Santiago-Walker, Ademi E., Letrero, Richard, D’Andrea, Kurt, Pushparajan, Anitha, Hayden, James E., Brown, Kimberly Dahlman, Laquerre, Sylvie, McArthur, Grant A., Sosman, Jeffrey A., Nathanson, Katherine L., Herlyn, Meenhard
פורמט: Artigo
שפה:Inglês
יצא לאור: 2010
נושאים:
Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3026446/
https://ncbi.nlm.nih.gov/pubmed/21156289
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccr.2010.11.023
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים